Neuphoria Therapeutics Inc. (NEUP) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
NEUP currently has 5.41M outstanding shares. with limited dilution risk as only 1.05M additional shares (19.5%) are authorized for issuance. The company has significantly diluted shareholders by 400.61% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 15, 2026 |
10-Q filing | 5.4M shares outstanding |
5.4M | 1.1M |
| Nov 14, 2025 |
10-Q filing | 5.4M shares outstanding |
5.4M | 1.1M |
| May 20, 2025 |
10-Q filing | 1.7M shares outstanding |
1.7M | 1.1M |
| Feb 14, 2025 |
10-Q filing | 1.8M shares outstanding |
1.8M | 1.1M |
| Jan 24, 2025 |
S-3 filing: This prospectus relates to the offer and resale from time to time by the selling shareholder identified in this prospectus of up to 1,054,381 shares of common stock of Neuphoria Therapeutics Inc. |
2.7M | 1.1M |
| Jan 07, 2025 |
S-3/A filing: Bionomics Limited files an S-3/A registration statement to offer and sell up to $100,000,000 in common stock and debt securities from time to time, and up to $2,000,000 in common stock through an at-the-market offering with H.C. Wainwright & Co. as sales agent. |
1.6M | 0 |
| Dec 23, 2024 |
POS AM filing: Bionomics Limited terminated the effectiveness of its registration statement due to the completion of a redomiciliation, removing all unsold securities from registration. |
3.5B | 0 |
| Dec 23, 2024 |
POS AM filing: This is a Post-Effective Amendment No. 1 terminating the effectiveness of the Registration Statement and removes from registration any and all securities registered but unsold under the Registration Statement as of the date hereof. |
3.5B | 0 |
| Nov 25, 2024 |
S-3/A filing: The Registration Statement includes two prospectuses: (i) a base prospectus to the proposed offer by the Company of its ordinary shares and its American Depositary Shares representing its Shares, various series of debt securities or warrants to purchase any such securities, and (ii) a sales agreement prospectus relating to the Company's at the market offering of up to an aggregate of US$2,000,000 of its Shares or ADSs. |
3.5B | 250M |
| Nov 18, 2024 |
S-3 filing: The company is filing an S-3 to offer up to $100,000,000 in American Depositary Shares and Debt Securities, and an ATM offering of American Depositary Shares for up to $2,000,000 through H.C. Wainwright & Co., LLC. |
3.5B | 250M |
| Nov 14, 2024 |
10-Q filing | 3514.9M shares outstanding |
3.5B | 250M |
| Sep 30, 2024 |
10-K filing | 3117.7M shares outstanding |
3.1B | 250M |
| Jun 18, 2024 |
F-1 filing: Private placement of ordinary shares represented by ADSs, pre-funded warrants, and accompanying warrants to purchase ADSs, resulting in proceeds of US$7.5 million before deducting offering expenses, with the intention to fund BNC210's registrational programs, business development activities, working capital, and general corporate purposes. |
1.5B | 250M |
| Oct 18, 2023 |
20-F filing | 1486.7M shares outstanding |
1.5B | 0 |
| May 05, 2023 |
F-3 filing: The company may offer and sell up to $180,000,000 in the aggregate of American Depositary Shares Representing Ordinary Shares and Debt Securities from time to time in one or more offerings. |
1.4B | 0 |
| Oct 14, 2022 |
20-F filing | 1353.4M shares outstanding |
1.4B | 0 |